Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
72 participants
INTERVENTIONAL
2006-12-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke
NCT03519737
Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
NCT01098981
Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke
NCT01678495
Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic
NCT05415150
Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke
NCT00507806
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRX-801
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Occlusion demonstrated by transcranial Doppler ultrasound
* Eligible for tPA
Exclusion Criteria
* Moderate to severe COPD
* Uncontrolled hypertension
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImaRx Therapeutics
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlos Molina Cateriano, MD
Role: STUDY_DIRECTOR
University Hospital Vall d'Hebron, Barcelona, Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Barrow Neurology Clinics at St. Joseph's Hospital
Phoenix, Arizona, United States
Hoag Memorial Hospital
Newport Beach, California, United States
California Pacific Medical Center
San Francisco, California, United States
Colorado Neurological Institute
Englewood, Colorado, United States
Christiana Care Health System
Newark, Delaware, United States
University of Miami
Miami, Florida, United States
St. Louis University School of Medicine
St Louis, Missouri, United States
University of Rochester
Rochester, New York, United States
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
Methodist Hospital Neurological Institute
Houston, Texas, United States
University of Texas
Houston, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
Bichat - Claude Bernard University Hospital and Medical School
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRX-06-101-CP-01-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.